Treatment with anti-IL-18 antibody corrects liver defects in Il18bp−/− mice and ameliorates inflammation and fibrosis in diet-induced MASH mice, suggesting a translational treatment opportunity. The gene discussed is IL18; the disease is metabolic dysfunction-associated steatohepatitis.